Lactate-Driven HMGB1 Modification and Exosomal Release in Polymicrobial Sepsis: Mechanistic Insights and Research Applications

Study Background and Research Question

Sepsis remains a leading cause of mortality in intensive care units worldwide, characterized by dysregulated inflammation and multi-organ dysfunction. Elevated serum lactate is a clinically established biomarker for sepsis severity, yet the mechanistic consequences of lactate accumulation in immune cell function remain incompletely understood. High mobility group box-1 (HMGB1), a nuclear protein and late-phase pro-inflammatory mediator, is known to be released from activated macrophages and is linked to poor outcomes in sepsis. While prior clinical observations have correlated circulating HMGB1 and lactate levels, the causative relationship and underlying molecular pathways remained unclear.

Key Innovation from the Reference Study

The reference study by Yang et al. (Cell Death & Differentiation, 2022) provides the first direct evidence that lactate not only correlates with, but actively promotes HMGB1 lactylation and acetylation in macrophages during polymicrobial sepsis. The authors identify distinct, converging molecular pathways by which extracellular lactate drives these post-translational modifications (PTMs) of HMGB1, leading to its exosomal release and subsequent increase in endothelial permeability. This positions the lactate-HMGB1 axis as a critical, targetable node in sepsis pathogenesis.

Methods and Experimental Design Insights

The study employs a multi-tiered experimental framework combining in vivo murine sepsis models, ex vivo macrophage cultures, and molecular intervention strategies. Key methodological highlights include:

• Use of cecal ligation and puncture (CLP) to induce polymicrobial sepsis in wild-type and genetically engineered mice (including macrophage-specific YAP knockout models) to dissect cell-specific signaling events.
• Measurement of serum lactate and exosomal HMGB1 levels using established biochemical assays, providing quantitative links between systemic metabolic shifts and inflammatory mediators.
• Macrophage exposure to exogenous lactate, coupled with pharmacological inhibitors and genetic knockdowns (e.g., of p300/CBP, SIRT1, β-arrestin2), to delineate upstream and downstream effectors in the HMGB1 modification pathway.
• Immunoprecipitation and mass spectrometry to confirm lactylation and acetylation of HMGB1 at specific lysine residues.
• Functional assays assessing endothelial cell permeability in response to macrophage-derived exosomes, linking molecular changes to physiologically relevant outcomes.

Core Findings and Why They Matter

The study’s principal findings elucidate a multifaceted mechanism by which lactate modulates macrophage inflammatory outputs in sepsis:

• Lactate Uptake and Modification: Extracellular lactate is imported into macrophages via monocarboxylate transporters (MCTs), where it fuels p300/CBP-dependent lactylation of HMGB1. Concurrently, lactate enhances HMGB1 acetylation through suppression of the deacetylase SIRT1, a process requiring Hippo/YAP and β-arrestin2-mediated nuclear recruitment of acetyltransferases via GPR81 signaling.
• Exosomal HMGB1 Release: These PTMs facilitate the translocation of HMGB1 from the nucleus to the cytoplasm, promoting its packaging into exosomes for extracellular release. This exosomal HMGB1 markedly increases endothelial cell permeability, a hallmark of septic vascular dysfunction.
• Therapeutic Implications: Pharmacological inhibition of lactate production or blockade of GPR81 signaling reduces circulating exosomal HMGB1 and improves survival in septic mice. This highlights the therapeutic potential of targeting lactate-driven signaling in the context of inflammatory signaling pathway research.

Collectively, these results establish lactate as a direct modulator of HMGB1-driven inflammation, moving beyond its traditional role as a metabolic byproduct or biomarker.

Comparison with Existing Internal Articles

This mechanistic advance complements and extends insights from recent translational research literature. For example, the article "Beyond Pathway Inhibition: Strategic Horizons for Translational Research" discusses how Bay 11-7821 (BAY 11-7082), a selective IKK inhibitor, can be used to dissect NF-κB pathway modulation in the context of lactate-driven inflammation and HMGB1 release. This internal analysis highlights the value of integrating specific pathway inhibitors with mechanistic studies of metabolic-immune crosstalk. Similarly, guides such as "Bay 11-7821: Selective IKK Inhibitor for NF-κB Research" underscore the utility of pharmacological tools for probing apoptosis regulation and inflammatory signaling, which align with the reference study’s focus on PTMs and exosomal signaling in macrophages.

Other scenario-driven protocols (e.g., "Advanced Insights into NF-κB and Apoptosis Regulation") provide workflow recommendations for combining pathway inhibitors with readouts such as cell viability, exosome release, and cytokine profiling, offering synergistic experimental approaches for researchers studying the lactate-HMGB1 axis.

Limitations and Transferability

While the study robustly demonstrates lactate’s direct effects on HMGB1 modification and release in murine macrophage models, there are important limitations to consider:

• Species and Model Specificity: The findings are based primarily on mouse models and macrophage cell lines. Although human clinical correlations are cited, direct translational validation in patient-derived cells or tissues remains to be performed.
• Complexity of Sepsis Pathophysiology: Sepsis involves multiple cell types and signaling networks. The focus on macrophage-mediated HMGB1 release provides a crucial piece of the puzzle, but other immune and stromal cell contributions require further study.
• Pharmacological Targeting: While inhibitors of lactate metabolism and GPR81 signaling improved outcomes in mice, the safety and specificity of such interventions in humans warrant careful evaluation, especially given lactate’s roles in normal physiology and tissue repair.

Despite these caveats, the mechanistic clarity provided by the study offers a strong conceptual framework for future research in inflammatory signaling pathway research, apoptosis regulation studies, and translational sepsis interventions.

Protocol Parameters

• CLP model induction: Standard cecal ligation and puncture; optimal for modeling polymicrobial sepsis and systemic inflammation.
• Lactate treatment: Exogenous lactate (concentration and duration as per reference study protocols) to stimulate HMGB1 modification in vitro.
• IKK/NF-κB inhibition: Use selective pathway inhibitors such as Bay 11-7821 (BAY 11-7082) at literature-reported concentrations (e.g., 5–10 μM for cell-based assays) to modulate downstream signaling.
• Exosome isolation: Ultracentrifugation or commercial exosome isolation kits to collect macrophage-derived exosomes for functional assays.
• Macrophage-specific gene knockout: Cre/LoxP system for targeted deletion of YAP or related signaling molecules, validated by PCR genotyping.
• Endothelial permeability assay: Transwell or electrical resistance measurements to assess functional impacts of exosomal HMGB1.

Research Support Resources

To experimentally dissect the NF-κB and inflammatory signaling pathways highlighted in the reference study, researchers can leverage selective IKK inhibitors such as Bay 11-7821 (BAY 11-7082) (SKU A4210) from APExBIO. This compound has been shown to effectively inhibit IKK activity and downstream NF-κB signaling, supporting workflows in inflammation, apoptosis, and B-cell lymphoma research. For detailed protocol guidance, recent internal articles offer practical insights on optimizing experimental conditions and maximizing reproducibility when using pathway inhibitors in conjunction with metabolic or exosomal assays.